EA201891028A1 - Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv - Google Patents
Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hivInfo
- Publication number
- EA201891028A1 EA201891028A1 EA201891028A EA201891028A EA201891028A1 EA 201891028 A1 EA201891028 A1 EA 201891028A1 EA 201891028 A EA201891028 A EA 201891028A EA 201891028 A EA201891028 A EA 201891028A EA 201891028 A1 EA201891028 A1 EA 201891028A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- trispecific
- binding proteins
- hiv
- infection caused
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562246113P | 2015-10-25 | 2015-10-25 | |
| EP16305211 | 2016-02-24 | ||
| US201662322029P | 2016-04-13 | 2016-04-13 | |
| US201662331169P | 2016-05-03 | 2016-05-03 | |
| PCT/US2016/058540 WO2017074878A1 (en) | 2015-10-25 | 2016-10-24 | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201891028A1 true EA201891028A1 (ru) | 2019-02-28 |
Family
ID=55588187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891028A EA201891028A1 (ru) | 2015-10-25 | 2016-10-24 | Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv |
Country Status (31)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2820164C2 (ru) * | 2019-04-09 | 2024-05-30 | Санофи | Триспецифические и/или тривалентные связывающие белки с применением кроссоверного формата с двойным вариабельным доменом (codv) для лечения инфекции, вызванной hiv |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| WO2019135921A1 (en) * | 2017-12-21 | 2019-07-11 | Aaron Diamond Aids Research Center | Bispecific hiv-1-neutralizing antibodies |
| EP3778630A1 (en) * | 2014-02-28 | 2021-02-17 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region |
| PE20181167A1 (es) * | 2015-10-25 | 2018-07-19 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih |
| CN115010805B (zh) | 2015-11-03 | 2025-01-28 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1 gp41中和抗体及其用途 |
| BR112018070998A2 (pt) | 2016-04-13 | 2019-02-26 | Sanofi | proteínas de ligação triespecíficas e/ou trivalentes |
| HUE063824T2 (hu) * | 2016-04-13 | 2024-02-28 | Sanofi Sa | Trispecifikus és/vagy trivalens kötõfehérjék |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子 |
| US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| US11845787B2 (en) * | 2017-03-27 | 2023-12-19 | The Wistar Institute Of Anatomy And Biology | DNA antibody constructs for use against HIV |
| US10882907B2 (en) | 2017-06-21 | 2021-01-05 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
| JP7036909B2 (ja) * | 2017-10-10 | 2022-03-15 | サノフイ | 抗ｃｄ３８抗体および使用方法 |
| JP2021507717A (ja) * | 2017-12-18 | 2021-02-25 | ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ | 抗原結合性ポリペプチド |
| EP3737949A1 (en) | 2018-01-12 | 2020-11-18 | Genzyme Corporation | Methods for the quantitation of polypeptides |
| EP3797118A4 (en) | 2018-05-22 | 2022-06-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| KR20210075129A (ko) * | 2018-10-09 | 2021-06-22 | 사노피 | 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법 |
| US12459989B2 (en) * | 2018-11-21 | 2025-11-04 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (HIV) |
| TW202104274A (zh) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| WO2020210392A1 (en) * | 2019-04-09 | 2020-10-15 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| BR112022007664A2 (pt) | 2019-10-25 | 2022-08-09 | Sanofi Sa | Métodos para analisar o pareamento incorreto de cadeias em proteínas de ligação multiespecíficas |
| US20230203466A1 (en) * | 2020-04-03 | 2023-06-29 | Medgenome Inc. | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
| CA3187085A1 (en) | 2020-08-25 | 2022-03-03 | Manuel Baca | Multi-specific antigen binding molecules targeting hiv and methods of use |
| CA3232365A1 (en) * | 2021-09-29 | 2023-04-06 | Ronnie Rong Wei | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv |
| MX2024003808A (es) * | 2021-09-29 | 2024-06-11 | Modex Therapeutics Inc | Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos. |
| CN118591388A (zh) * | 2021-09-29 | 2024-09-03 | 摩德斯医疗股份有限公司 | 抗原结合多肽、抗原结合多肽复合物及其使用方法 |
| WO2025108551A1 (en) | 2023-11-23 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| WO2025109206A1 (en) | 2023-11-22 | 2025-05-30 | Mabylon Ag | Multispecific anti-allergen antibodies and uses thereof |
| US20250376537A1 (en) | 2024-05-17 | 2025-12-11 | Sanofi | Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| NZ527591A (en) | 2001-01-17 | 2006-04-28 | Trubion Pharmaceuticals Inc | Binding domain-immunoglobulin fusion proteins |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| WO2005000898A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CA2774636C (en) | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| US8637024B2 (en) | 2010-11-12 | 2014-01-28 | The Rockefeller University | Fusion antibodies for HIV therapy |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| TWI803876B (zh) | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| EP3865507A1 (en) * | 2011-05-17 | 2021-08-18 | The Rockefeller University | Human immunodeficiency virus neutralizing antibodies and methods of use thereof |
| WO2013070776A1 (en) | 2011-11-07 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing gp41 antibodies and their use |
| ES2749349T3 (es) * | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| CN108676091B (zh) | 2011-12-08 | 2022-04-01 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
| WO2013163427A1 (en) * | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP2900696A1 (en) * | 2012-09-25 | 2015-08-05 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| WO2014089152A1 (en) | 2012-12-04 | 2014-06-12 | University Of Maryland, Baltimore | Hiv-1 env-binding antibodies, fusion proteins, and methods of use |
| HK1213481A1 (zh) | 2012-12-13 | 2016-07-08 | The Trustees Of The University Of Pennsylvania | Dna抗体构建体及其使用方法 |
| US20140213772A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| EP2948475A2 (en) * | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| EA201891502A1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| WO2014144299A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα |
| EP3027755B1 (en) | 2013-08-02 | 2019-10-09 | The Regents of The University of California | Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors |
| BR112016009919A2 (pt) | 2013-11-04 | 2017-12-05 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma |
| EP3954713A3 (en) | 2014-03-28 | 2022-03-30 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| US10961506B2 (en) | 2014-09-04 | 2021-03-30 | Stemcell Technologies Inc. | Soluble antibody complexes for T cell or NK cell activation and expansion |
| EP3247725B1 (en) | 2015-01-23 | 2020-07-01 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| EP3298389B1 (en) | 2015-05-20 | 2021-09-29 | Quantum-Si Incorporated | Method of determining the sequence of a nucleic acid using time resolved luminescence |
| US10654943B2 (en) | 2015-06-02 | 2020-05-19 | The Rockefeller University | Tri-specific antibodies for HIV therapy |
| MX2018003463A (es) | 2015-09-22 | 2018-09-06 | Univ Pennsylvania | Método de redireccionamiento de células t para tratar la infección por virus de inmunodeficiencia humana (vih). |
| PE20181167A1 (es) | 2015-10-25 | 2018-07-19 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih |
| CN105837688B (zh) | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 |
| EA201891186A1 (ru) | 2015-12-15 | 2018-12-28 | Джилид Сайэнс, Инк. | Антитела, нейтрализующие вирус иммунодефицита человека |
| HUE063824T2 (hu) | 2016-04-13 | 2024-02-28 | Sanofi Sa | Trispecifikus és/vagy trivalens kötõfehérjék |
| BR112018070998A2 (pt) | 2016-04-13 | 2019-02-26 | Sanofi | proteínas de ligação triespecíficas e/ou trivalentes |
| US12234479B2 (en) | 2016-12-30 | 2025-02-25 | Cytocares (Shanghai) Inc. | Bifunctional molecule and use thereof |
| JP7304288B2 (ja) | 2017-02-17 | 2023-07-06 | サノフイ | ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子 |
| US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| US11845787B2 (en) | 2017-03-27 | 2023-12-19 | The Wistar Institute Of Anatomy And Biology | DNA antibody constructs for use against HIV |
| JP7036909B2 (ja) | 2017-10-10 | 2022-03-15 | サノフイ | 抗ｃｄ３８抗体および使用方法 |
| KR20210075129A (ko) | 2018-10-09 | 2021-06-22 | 사노피 | 삼중특이적 항-cd38, 항-cd28, 및 항-cd3 결합 단백질 및 바이러스 감염을 치료하기 위한 사용 방법 |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2016
- 2016-10-24 PE PE2018000603A patent/PE20181167A1/es unknown
- 2016-10-24 WO PCT/US2016/058540 patent/WO2017074878A1/en not_active Ceased
- 2016-10-24 BR BR112018008011-0A patent/BR112018008011A2/en not_active Application Discontinuation
- 2016-10-24 SI SI201631358T patent/SI3365366T1/sl unknown
- 2016-10-24 CA CA3002664A patent/CA3002664A1/en active Pending
- 2016-10-24 PL PL16794472T patent/PL3365366T3/pl unknown
- 2016-10-24 JP JP2018521308A patent/JP7169190B2/ja active Active
- 2016-10-24 EP EP16794472.7A patent/EP3365366B1/en active Active
- 2016-10-24 RS RS20211266A patent/RS62437B1/sr unknown
- 2016-10-24 MY MYPI2018701634A patent/MY192278A/en unknown
- 2016-10-24 CN CN202310186776.6A patent/CN116789841A/zh active Pending
- 2016-10-24 AU AU2016347058A patent/AU2016347058B2/en active Active
- 2016-10-24 MX MX2018005048A patent/MX2018005048A/es unknown
- 2016-10-24 CR CR20180288A patent/CR20180288A/es unknown
- 2016-10-24 KR KR1020187014534A patent/KR102687212B1/ko active Active
- 2016-10-24 NZ NZ781602A patent/NZ781602A/en unknown
- 2016-10-24 EA EA201891028A patent/EA201891028A1/ru unknown
- 2016-10-24 MA MA42641A patent/MA42641A1/fr unknown
- 2016-10-24 HR HRP20211528TT patent/HRP20211528T1/hr unknown
- 2016-10-24 US US15/770,471 patent/US20190054182A1/en not_active Abandoned
- 2016-10-24 EP EP20197556.2A patent/EP3819310A1/en active Pending
- 2016-10-24 ES ES16794472T patent/ES2894304T3/es active Active
- 2016-10-24 SG SG11201803324VA patent/SG11201803324VA/en unknown
- 2016-10-24 CN CN201680075852.4A patent/CN109311966B/zh active Active
- 2016-10-24 CN CN202310147287.XA patent/CN116675776A/zh active Pending
- 2016-10-24 CN CN202310185803.8A patent/CN117069855A/zh active Pending
- 2016-10-24 HU HUE16794472A patent/HUE056608T2/hu unknown
- 2016-10-24 IL IL301140A patent/IL301140A/en unknown
- 2016-10-25 TW TW113100534A patent/TW202442675A/zh unknown
- 2016-10-25 UY UY0001036965A patent/UY36965A/es not_active Application Discontinuation
- 2016-10-25 AR ARP160103249A patent/AR106466A1/es unknown
- 2016-10-25 TW TW110126977A patent/TW202219064A/zh unknown
- 2016-10-25 TW TW105134405A patent/TWI750139B/zh active
-
2018
- 2018-04-20 DO DO2018000102A patent/DOP2018000102A/es unknown
- 2018-04-22 IL IL258822A patent/IL258822B2/en unknown
- 2018-04-23 CL CL2018001065A patent/CL2018001065A1/es unknown
- 2018-04-23 PH PH12018500873A patent/PH12018500873A1/en unknown
- 2018-04-24 MX MX2022014631A patent/MX2022014631A/es unknown
- 2018-05-22 CO CONC2018/0005337A patent/CO2018005337A2/es unknown
-
2019
- 2019-10-21 US US16/659,426 patent/US11129905B2/en active Active
-
2021
- 2021-02-04 JP JP2021016190A patent/JP7328267B2/ja active Active
- 2021-08-17 US US17/404,908 patent/US11779651B2/en active Active
-
2023
- 2023-04-06 JP JP2023061823A patent/JP7724814B2/ja active Active
-
2024
- 2024-01-22 AU AU2024200395A patent/AU2024200395A1/en active Pending
- 2024-11-26 US US18/960,890 patent/US20250312475A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2820164C2 (ru) * | 2019-04-09 | 2024-05-30 | Санофи | Триспецифические и/или тривалентные связывающие белки с применением кроссоверного формата с двойным вариабельным доменом (codv) для лечения инфекции, вызванной hiv |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891028A1 (ru) | Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv | |
| EA201892312A1 (ru) | Триспецифические и/или тривалентные связывающие белки | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| EA201991720A1 (ru) | Антитела к альфа-синуклеину и их применения | |
| JOP20200300A1 (ar) | أجسام مضادة لـ il-11ra | |
| EA202090296A1 (ru) | Спироциклические соединения и способы их получения и применения | |
| EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| EA202090312A1 (ru) | Спироциклические соединения и способы их получения и применения | |
| EA201891399A1 (ru) | Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний | |
| MX2020002406A (es) | Anticuerpo anti-epha4. | |
| EA201792561A1 (ru) | Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения | |
| MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| EA202191656A1 (ru) | Анти-il-36 антитела и способы их применения | |
| MX2023004804A (es) | Proteinas de union triespecificas y/o trivalentes. | |
| EA202191078A2 (ru) | Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv | |
| TN2018000137A1 (en) | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection | |
| EA202092279A1 (ru) | Антитела к mica и/или micb и их применение | |
| AR118602A1 (es) | Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih | |
| EA202092981A1 (ru) | Антитела к l1cam и их применение | |
| EA201992747A1 (ru) | Антитела к fam19a5 и их применение | |
| TN2018000345A1 (en) | Trispecific and/or trivalent binding proteins |